Delivery Order SPE2DB22D2214-SPE2DB25FS3NT

Award Date 1/27/25
Potential Completion Date 1/28/25
Potential Value $7.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the pharmaceutical product OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, with a ceiling value of $8,673.68. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 held by Amerisourcebergen with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This federal contract award from the Defense Logistics Agency (DLA) is for the pharmaceutical product OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML. The $62,074.20 firm fixed price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on October 28, 2024 with an ultimate completion date of October 29, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML. The contract, valued at $5,099.03, is a delivery order issued by the Defense Logistics Agency (DLA), a defense agency. The contract has a firm fixed price pricing type and an ultimate completion date of December 5, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $8,375.24, is a delivery order for the pharmaceutical product OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML. The contract has a period of performance through February 11, 2025 and utilizes a firm fixed price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,595.93, is a Firm Fixed Price Delivery Order for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a pharmaceutical product. The contract has an ultimate completion date of January 31, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $3,733.92 firm-fixed-price delivery order is for the supply of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a prescription medication. The contract has a performance period ending on July 22, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at up to $999,999,999...
This federal contract award is for the delivery of OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $5,593.82 and is a firm fixed price delivery order with an ultimate completion date of August 30, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,040.26, is for the delivery of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a pharmaceutical product. The contract has an ultimate completion date of December 21, 2023. This award is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ozempic 1 mg/dose (4 mg/3 ml) 3 ml medication. The contract, valued at $3,014.56, is a delivery order under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, worth up to $999,999,999 and running through November 2026. The IDC enables the DLA to efficiently procure a comprehensive range of pharmaceutical products and medical...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,483.24 delivery order contract is for the supply of OZEMPIC 2 MG/DOSE (8 MG/3 ML) 3ML, a specialty pharmaceutical product. The contract has a firm fixed price pricing type and an ultimate completion date of September 27, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) valued at...
  • SPE2DB22D2214
    Indefinite Delivery Contract
  • SPE2DB22D2214-SPE2DB25FS3NT
    Delivery Order

This federal contract award is for the pharmaceutical product OZEMPIC 1 MG/DOSE (4 MG/3 ML) 3ML, which was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,605.67, is a delivery order placed under an Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, worth up to $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has a firm fixed price, with a completion date of January 28, 2025. The contract award does not have a set-aside designation, indicating open competition.

Generated 5/21/25, 9:55 AM